Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.82
-0.26 (-2.58%)
At close: Apr 28, 2026, 4:00 PM EDT
10.01
+0.19 (1.93%)
After-hours: Apr 28, 2026, 7:44 PM EDT
CRBP Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for CRBP stock have an average target of 45.6, with a low estimate of 38 and a high estimate of 57. The average target predicts an increase of 364.36% from the current stock price of 9.82.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 10, 2026.
Analyst Ratings
The average analyst rating for CRBP stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 2 |
| Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $53 → $57 | Buy | Maintains | $53 → $57 | +480.45% | Mar 10, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $55 → $53 | Buy | Maintains | $55 → $53 | +439.71% | Nov 13, 2025 |
| Wedbush | Wedbush | Buy Maintains $31 → $38 | Buy | Maintains | $31 → $38 | +286.97% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +307.33% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +307.33% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
1.70M
Revenue Next Year
3.67M
from 1.70M
Increased by 116.00%
EPS This Year
-4.68
from -5.90
EPS Next Year
-5.00
from -4.68
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.5M | 21.0M | ||||||
| Avg | 1.7M | 3.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,135.3% | ||||||
| Avg | - | 116.0% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.26 | -2.45 | ||||||
| Avg | -4.68 | -5.00 | ||||||
| Low | -5.63 | -7.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.